Center for Biologics Evaluation and Research

Center for Biologics Evaluation and Research
Name	Center for Biologics Evaluation and Research
Jurisdiction	United States Department of Health and Human Services
Headquarters	Silver Spring, Maryland
Parent agency	Food and Drug Administration

Center for Biologics Evaluation and Research is the component of the Food and Drug Administration responsible for the regulation and evaluation of biological products in the United States, including vaccines, blood products, cellular therapies, and gene therapies. The Center operates within the administrative and legal framework shaped by statutes such as the Biologics Control Act of 1902, the Public Health Service Act, and amendments from the Food, Drug, and Cosmetic Act, interacting routinely with agencies like the Centers for Disease Control and Prevention, the National Institutes of Health, the Department of Defense, and international counterparts such as the European Medicines Agency and the World Health Organization. Its activities intersect with high-profile events and programs including pandemic responses to H1N1 influenza, COVID-19 pandemic, and vaccine development efforts tied to institutions like Moderna, Inc., Pfizer, Johnson & Johnson, and AstraZeneca.

History

The Center traces its roots through regulatory milestones associated with the Biologics Control Act of 1902, the formation of the Food and Drug Administration, and postwar expansions influenced by the National Institutes of Health era and the Kefauver Harris Amendment period. Key moments include regulatory responses to the Tuskegee syphilis experiment revelations, the rise of vaccinology following work at the Rockefeller Institute, shifts after the 1962 Thalidomide safety concerns that influenced biologicals oversight, and structural changes during the administrations of presidents like Richard Nixon and Jimmy Carter which reshaped federal health science capacities. The Center’s evolution paralleled advances at research centers such as Johns Hopkins Hospital, Centers for Disease Control and Prevention, and collaborations with academic hubs including Harvard Medical School, Stanford University School of Medicine, and Massachusetts Institute of Technology.

Mission and Responsibilities

The Center’s mission statement aligns with statutory duties in the Public Health Service Act and regulatory mandates under the Federal Food, Drug, and Cosmetic Act to ensure the safety, effectiveness, and availability of biological products. Responsibilities include premarket review of biological license applications from manufacturers such as Sanofi, GlaxoSmithKline, and Regeneron Pharmaceuticals; postmarket surveillance in coordination with the Vaccine Adverse Event Reporting System and MedWatch; and regulatory policy development that engages stakeholders including Pharmaceutical Research and Manufacturers of America and patient advocacy organizations tied to conditions like hemophilia and HIV/AIDS. The Center also adjudicates issues involving emergency authorization mechanisms similar to the Emergency Use Authorization framework used during the COVID-19 pandemic.

Regulatory Activities and Policies

Regulatory activities encompass licensing, inspection, and enforcement actions guided by scientific reviews, Good Manufacturing Practices derived from the Code of Federal Regulations, and international standards like those from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Policy instruments include biologics license applications, guidance documents invoked during crises such as 2009 H1N1 influenza pandemic, and collaborative regulatory pathways with the European Medicines Agency and Health Canada. Enforcement actions have been applied in cases involving counterfeit or adulterated products similar in profile to historical incidents connected to entities investigated by the Federal Bureau of Investigation or litigated in federal courts such as the United States District Court for the District of Columbia.

Organizational Structure

The Center is organized into offices and divisions that oversee product-specific portfolios and scientific functions, including components parallel to those at the National Institutes of Health such as review divisions, laboratories, and policy units. Leadership and advisory interfaces have included interactions with advisory committees modeled on the Vaccines and Related Biological Products Advisory Committee and collaborations with the Advisory Committee on Immunization Practices at the Centers for Disease Control and Prevention. The Center works with legal and administrative entities like the Office of Management and Budget and congressional overseers including committees of the United States Senate and the United States House of Representatives.

Research and Scientific Programs

Scientific programs support preclinical and clinical evaluation, biologics manufacturing science, and translational research in areas like vaccinology, monoclonal antibodies, gene therapy, and cell-based therapeutics. Research collaborations have linked the Center to institutions such as the National Cancer Institute, Eli Lilly and Company research initiatives, and university-based centers at University of California, San Francisco and University of Pennsylvania Perelman School of Medicine. The Center’s laboratories conduct work informed by historical research traditions from the Rockefeller University and modern biotechnology firms including CRISPR Therapeutics and Bluebird Bio, addressing technical challenges evident in landmark cases like gene therapy trials at University of Pennsylvania.

Emerging Issues and Public Health Impact

Emerging issues center on next-generation modalities—gene editing, mRNA platforms, and regenerative medicine—raising complex questions involving biosecurity frameworks from Department of Homeland Security, ethical considerations engaged by institutions such as the Hastings Center, and global access debates featuring the World Health Organization and Gavi, the Vaccine Alliance. The Center’s regulatory choices influence public health outcomes in outbreaks linked to pathogens like Ebola virus disease and influenza subtypes, impact supply chains involving manufacturers such as Novartis and Bayer, and shape policy discourse in forums including the Pan American Health Organization and international regulatory summits attended by delegations from Japan and United Kingdom governments.

Category:Food and Drug Administration